Schikan Johannes Gerardus Christiaan Petrus sold $29K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 800 shares of Pharvaris N.V. (PHVS) at $36.19 on 2026-09-22.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Sep 24, 2026, 2:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosed sale is modest and does not suggest a change in insider confidence.

02

Market read

Small insider sale; limited relevance for traders.

03

Timing

filing date 2026-09-24

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-24

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

Director Schikan sold 800 shares for $28,952, reducing his holdings to 115,167 shares.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to float and no broader market implications.

Key entities

  • Pharvaris N.V.

    Biotech company listed on Nasdaq under ticker PHVS.

  • Schikan Johannes Gerardus Christiaan Petrus

    Director of Pharvaris who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.